Current and future trends in the use of immunosuppressive agents in patients with uveitis

Matthias D. Becker, James T. Rosenbaum

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Therapeutic trials for uveitis are seldom performed because of the relative rarity of the disease and its heterogeneity. Promising new approaches to therapy include cytokine or cytokine receptor inhibition; cytokine addition (α-interferon or interleukin-10); novel anti-metabolites; combination therapies; intravenous immunoglobulin; intravitreally inserted corticosteroid implants; and oral tolerance. Additional modalities or targets that deserve further testing include T-cell subsets, adhesion molecules, accessory molecules in antigen presentation, novel inflammatory mediators, inducers of apoptosis, photodynamic therapy, and neuroprotective agents. (C) 2000 Lippincott Williams and Wilkins, Inc.

Original languageEnglish (US)
Pages (from-to)472-477
Number of pages6
JournalCurrent opinion in ophthalmology
Volume11
Issue number6
DOIs
StatePublished - 2000

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Current and future trends in the use of immunosuppressive agents in patients with uveitis'. Together they form a unique fingerprint.

Cite this